Wedbush Reiterated an Outperform on Cerulean Pharma (CERU) Following 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101
November 17, 2015 7:00 AM ESTThree-Party Collaboration Will Explore Synergies Between AstraZenecas Leading PARP Inhibitor and Ceruleans Topoisomerase Inhibitor
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (Nasdaq: CERU) announced today that it has entered into a collaboration with AstraZeneca AB (AstraZeneca) and the National Cancer Institute (NCI), part of the National Institutes of Health, to... More
Cerulean Reports Third Quarter 2015 Corporate Highlights and Financial Results
November 16, 2015 4:35 PM ESTConference Call Today at 4:30 p.m.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended September 30, 2015.
During the third quarter, we strengthened our management team by appointing... More
